Skip to main content

Table 2 Univariate analysis of the association of lysozyme with relapse-free survival

From: Expression and prognostic significance of lysozyme in male breast cancer

   Relapse-free survival (%)  
Patient and tumor characteristics n 5 years (% ± s.e.) 10 years (% ± s.e.) P
Age     n.s.
   <60 16 100 66 ± 27  
   ≥ 60 41 71 ± 8 71 ± 8  
Tumor size     n.s.
   T1 20 76 ± 12 50 ± 2  
   T2 19 94 ± 5 94 ± 5  
   T3-T4 18 64 ± 13 -  
Nodal status     <0.005
   N0 32 95 ± 4 95 ± 4  
   N+ 25 61 ± 11 41 ± 18  
Histological grade     n.s.
   I 12 100 -  
   II 25 81 ± 8 81 ± 8  
   III 20 68 ± 12 41 ± 18  
Lysozyme*     <0.05
   ≥ 100 25 64 ± 11 64 ± 11  
   <100 84 93 ± 4 75 ± 17  
  1. *Semiquantitive immunostaining score. s.e. = standard error; n.s. = not significant.